ESDO: esdo GI bullets
The addition of Pembrolizumab to perioperative chemotherapy increases the pCR rate, but does not improve the event-free survival (EFS) in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585). In a multicentre, randomised, placebo-controlled, phase III study, 1007 patients with locally advanced gastric or gastro-esophageal adenocarcinoma (≥cT3 i/lub N+) were randomly assigned to either the pembrolizumab plus perioperative chemotherapy group, or the placebo plus perioperative chemotherapy